Alumis Inc. (NASDAQ:ALMS – Get Free Report)’s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $12.54, but opened at $12.25. Alumis shares last traded at $12.40, with a volume of 2,121 shares changing hands.
Analysts Set New Price Targets
A number of equities research analysts recently issued reports on ALMS shares. Cantor Fitzgerald began coverage on shares of Alumis in a research report on Tuesday, July 23rd. They set an “overweight” rating and a $13.00 target price for the company. Guggenheim initiated coverage on shares of Alumis in a report on Tuesday, July 23rd. They set a “buy” rating and a $32.00 price objective for the company. Morgan Stanley initiated coverage on shares of Alumis in a research note on Tuesday, July 23rd. They issued an “overweight” rating and a $36.00 target price for the company. SVB Leerink assumed coverage on Alumis in a research report on Tuesday, July 23rd. They set an “outperform” rating and a $29.00 price target on the stock. Finally, Leerink Partnrs raised Alumis to a “strong-buy” rating in a report on Tuesday, July 23rd. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Alumis currently has a consensus rating of “Buy” and an average price target of $27.50.
Read Our Latest Stock Analysis on ALMS
Alumis Price Performance
Institutional Trading of Alumis
Alumis Company Profile
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
Read More
- Five stocks we like better than Alumis
- How to Invest in Tech StocksĀ and Top Tech Stocks to Consider
- 3 Stocks That Could Beat the September Blues
- The Risks of Owning Bonds
- Canopy Growth Stock: Can It Sustain Recent Gains?
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Serve Robotics Is Serving Up a Selling Opportunity
Receive News & Ratings for Alumis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alumis and related companies with MarketBeat.com's FREE daily email newsletter.